SLCO1B1与CYP2C9变异对他汀药代动力学的影响
该临床试验在173名和164名健康受试者中研究单剂普伐他汀与匹伐他汀的药代遗传学,并纳入96名既往研究受试者。全基因组荟萃分析显示SLCO1B1 c.521T>C与两种他汀AUC0-∞升高全基因组显著相关,CYP2C9变异可能影响匹伐他汀暴露。
要点
- SLCO1B1 c.521T>C与普伐他汀、匹伐他汀AUC0-∞升高全基因组显著相关
- SLCO1B1功能减低者普伐他汀和匹伐他汀暴露升高,功能增强者普伐他汀暴露降低
- CYP2C9中间代谢型者匹伐他汀AUC0-∞较正常代谢型高18%
核心结论
- SLCO1B1在普伐他汀和匹伐他汀药代动力学中起重要作用,CYP2C9变异也影响匹伐他汀药代动力学。
研究设计与样本
- 临床试验研究单剂普伐他汀和匹伐他汀药代动力学,纳入173名和164名健康受试者,另从既往药物遗传学研究纳入96名普伐他汀受试者。
- 普伐他汀全基因组荟萃分析共纳入全部269名受试者。
主要发现
- 普伐他汀荟萃分析中SLCO1B1 c.521T>C(rs4149056)与AUC0-∞升高相关(P = 9.8 × 10-12)。
- 匹伐他汀中SLCO1B1 c.521T>C与AUC0-∞升高全基因组显著相关(P = 9.7 × 10-15)。
- 候选基因分析提示SLCO1B1功能增强变异者普伐他汀暴露降低,CYP2C9功能减低变异可能增加匹伐他汀及匹伐他汀内酯暴露。
关键数值与推荐
- 较SLCO1B1正常功能基因型者,功能差和功能减低者的普伐他汀AUC0-∞分别高140%(90% CI:86-210%;P = 4.7 × 10-8)和37%(20-56%;P = 1.1 × 10-4)。
- SLCO1B1功能高度增强基因型者普伐他汀AUC0-∞低60%(39-75%;P = 6.0 × 10-4)。
- 较正常功能者,SLCO1B1功能差和功能减低者的匹伐他汀AUC0-∞分别高153%(100-222%;P = 1.6 × 10-9)和35%(8-69%;P = 0.027)。
- CYP2C9中间代谢型者匹伐他汀AUC0-∞较正常代谢型者高18%(3-34%;P = 0.046)。
临床怎么用
- 对使用普伐他汀或匹伐他汀的患者,可关注SLCO1B1 c.521T>C(rs4149056)功能状态以评估暴露差异。
- 匹伐他汀用药可结合CYP2C9代谢型评估暴露升高的可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A clinical trial was carried out to investigate the pharmacogenetics of single-dose pravastatin and pitavastatin pharmacokinetics in 173 and 164 healthy participants. Additionally, 96 participants were included from previous pharmacogenetic studies with pravastatin. In a genome-wide meta-analysis of pravastatin including all 269 participants, SLCO1B1 c.521T>C (rs4149056) was associated with increased AUC0-∞ (P = 9.8 × 10-12). Similarly, SLCO1B1 c.521T>C was genome-wide significantly associated with increased AUC0-∞ of pitavastatin (P = 9.7 × 10-15). Candidate gene analyses suggested that participants with increased function SLCO1B1 variants had decreased pravastatin exposure. Furthermore, decreased function CYP2C9 variants may increase pitavastatin and pitavastatin lactone exposure. Compared to participants with normal function SLCO1B1 genotype, the AUC0-∞ of pravastatin was 140% (90% confidence interval: 86-210%; P = 4.7 × 10-8) and 37% (20-56%; P = 1.1 × 10-4) greater in participants with poor and decreased function SLCO1B1 genotype, respectively, while participants with highly increased function SLCO1B1 genotype had a 60% (39-75%; P = 6.0 × 10-4) lower AUC0-∞. The AUC0-∞ of pitavastatin was 153% (100-222%; P = 1.6 × 10-9) and 35% (8-69%; P = 0.027) greater in participants with poor and decreased function SLCO1B1 genotype, respectively, than in those with normal function SLCO1B1 genotype. Participants with intermediate metabolizer CYP2C9 genotype had 18% (3-34%; P = 0.046) greater AUC0-∞ of pitavastatin than those with normal metabolizer CYP2C9 genotype. This study demonstrates the important role of SLCO1B1 in pravastatin and pitavastatin pharmacokinetics and suggests that CYP2C9 variants also affect the pharmacokinetics of pitavastatin.
引用
- Mykkänen AJH, Tarkiainen EK, Taskinen S, et al. Identification of Genetic Variants Associated with Pravastatin and Pitavastatin Pharmacokinetics. Clin Pharmacol Ther. 2025. PMID: 40029062. doi:10.1002/cpt.3623
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。